PARP1 and breast carcinoma: Amongthem, HF4 emerged as a promising candidate, displaying single-digitinhibitory activity against both targets, further validated by itsstrong antiproliferative effect against three breast cancer cells.Due to the significant impact of PARP1 in oncology, the newly developedcheminformatics approach presented in this study can be similarlyemployed for exploring inhibitors targeting PARP1 and other associatedtargets, including PI3Kα and EZH2.34 Comprehensive details of these results are presented herein.